Drug Evaluation Committee Survey on Benefit-Risk Assessment of Post-Marketing Drugs "From the Outcome of IMI-PROTECT
Pharmacovigilance Subcommittee
July 2016
IMI-PROTECT is a grand EU project led by the EMA with the aim of enhancing benefit-risk assessment and safety surveillance of medicinal products from a scientific perspective. PROTECT and compiled them into a slide presentation. We hope that this document will be of help to you in your future drug safety surveillance activities.
Please note that this document may be modified from the original material as appropriate for the purpose of better understanding. The information in this document is current as of March 2016. It is assumed that links to quoted materials, etc., may change depending on circumstances. Please use this document with this understanding.
Deliverables of the Drug Evaluation Committee Return to list of all deliverables